Advertisement

Economic Change and Restructuring

, Volume 52, Issue 3, pp 255–277 | Cite as

Stock market behavior of pharmaceutical industry in Iran and macroeconomic factors

  • Hassan Heidari
  • Arash Refah Kahriz
  • Yousef MohammadzadehEmail author
Article
  • 141 Downloads

Abstract

This paper is the first attempt to evaluate the behavior of Iran’s pharmaceutical industry in light of challenges and variations. The pharmaceutical industry can be examined from two dimensions, namely, supply and demand. With respect to the demand side, the aging population, growing urbanization, and people’s changing preferences have been identified as the major issues shaping this demand in Iran in recent years. Regarding the supply as the main focus of this paper, we examine the effect of the most important macroeconomic variables such as inflation rate of health care, oil price shocks and money growth in the pharmaceutical industry. We investigate the influencing factors through impulse response analysis and variance decomposition analysis by collecting monthly data from 2005:1 to 2016:3. The results of this study demonstrate that pharmaceutical price has increased recently, and widespread changes have occurred in the Iranian’s pharmaceutical industry. Moreover, our findings indicate that the money growth and inflation rate of health care are the most influential factors in the pharmaceutical industry in Iran, during the period of study.

Keywords

Health care Macroeconomic factors Pharmaceutical industry Vector autoregressive model 

JEL Classification

G40 I11 I12 L11 L16 

Notes

Acknowledgements

The authors would like to thank the editor and anonymous referees for their comments and suggestions have significantly improved the earlier version of this research. All remaining errors and omissions are our own responsibility.

References

  1. Apergis N, Miller SM (2009) Do structural oil-market shocks affect stock prices? Energy Economics 31(4):569–575Google Scholar
  2. Bardey D, Bommier A, Jullien B (2010) Retail price regulation and innovation: reference pricing in the pharmaceutical industry. J Health Econ 29(2):303–316Google Scholar
  3. Bekaert G, Hoerova M, Duca ML (2013) Risk, uncertainty and monetary policy. J Monet Econ 60(7):771–788Google Scholar
  4. Benderly J, Zwick B (1985) Inflation, real balances, output, and real stock returns. Am Econ Rev 75(5):1115–1123Google Scholar
  5. Bernanke BS, Kuttner KN (2005) What explains the stock market’s reaction to Federal Reserve policy? J Financ 60(3):1221–1257Google Scholar
  6. Bhanja N, Dar AB, Tiwari AK (2012) Are stock prices hedge against inflation? A revisit over time and frequencies in India. Cent Eur J Econ Model Econ 4(3):199–213Google Scholar
  7. Bloom DE, Canning D, Sevilla J (2004) The effect of health on economic growth: a production function approach. World Dev 32(1):1–13Google Scholar
  8. Bomfim AN (2003) Pre-announcement effects, news effects, and volatility: monetary policy and the stock market. J Bank Financ 27(1):133–151Google Scholar
  9. Bouakez H, Essid B, Normandin M (2013) Stock returns and monetary policy: are there any ties? J Macroecon 36:33–50Google Scholar
  10. Boudoukh J, Richardson M (1993) Stock returns and inflation: a long-horizon perspective. Am Econ Rev 83(5):1346–1355Google Scholar
  11. Bouri E (2015) Return and volatility linkages between oil prices and the Lebanese stock market in crisis periods. Energy 89:365–371Google Scholar
  12. Brooks C (2014) Introductory econometrics for finance. Cambridge University Press, CambridgeGoogle Scholar
  13. Chen SS (2007) Does monetary policy have asymmetric effects on stock returns? J Money Credit Bank 39(2–3):667–688Google Scholar
  14. Chuliá H, Martens M, van Dijk D (2010) Asymmetric effects of federal funds target rate changes on S&P100 stock returns, volatilities and correlations. J Bank Financ 34(4):834–839Google Scholar
  15. Chun N, Park M (2013) The impact of health insurance mandates on drug innovation: evidence from the United States. Eur J Health Econ 14(2):323–344Google Scholar
  16. Ciner C (2001) Energy shocks and financial markets: nonlinear linkages. Stud Nonlinear Dyn Econom 5(3):203–212Google Scholar
  17. Comanor WS, Scherer FM (2013) Mergers and innovation in the pharmaceutical industry. J Health Econ 32(1):106–113Google Scholar
  18. Crowder WJ (2006) The interaction of monetary policy and stock returns. J Financ Res 29(4):523–535Google Scholar
  19. Cunado J, de Gracia FP (2014) Oil price shocks and stock market returns: evidence for some European countries. Energy Econ 42:365–377Google Scholar
  20. Degiannakis S, Filis G, Kizys R (2014) The effects of oil price shocks on stock market volatility: evidence from European data. Energy J 35(1):35–56Google Scholar
  21. Dierks RML, Bruyère O, Reginster JY, Richy FF (2016) Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Expert Rev Pharmacoecon Outcomes Res 16(5):571–578Google Scholar
  22. DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33Google Scholar
  23. Durai SRS, Bhaduri SN (2009) Stock prices, inflation and output: evidence from wavelet analysis. Econ Model 26(5):1089–1092Google Scholar
  24. Elian MI, Kisswani KM (2017) Oil price changes and stock market returns: cointegration evidence from emerging market. Econ Change Restruct.  https://doi.org/10.1007/s10644-016-9199-5 Google Scholar
  25. Elyasiani E, Mansur I, Odusami B (2011) Oil price shocks and industry stock returns. Energy Econ 33(5):966–974Google Scholar
  26. Engsted T, Tanggaard C (2002) The relation between asset returns and inflation at short and long horizons. J Int Financ Mark Inst Money 12(2):101–118Google Scholar
  27. Geske R, Roll R (1983) The fiscal and monetary linkage between stock returns and inflation. J Financ 38(1):1–33Google Scholar
  28. Gilchrist S, Leahy JV (2002) Monetary policy and asset prices. J Monet Econ 49(1):75–97Google Scholar
  29. Godman B, Gustafsson LL (2013) A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy 11(1):79–82Google Scholar
  30. Gonzalez CI, Gimeno R (2008) Financial analysts impact on stock volatility: a study on the pharmaceutical sector. fundación de estudios de economía aplicada (fedea), 1–28. FEDEA Working Paper No. 2008–19. Available at SSRN: https://ssrn.com/abstract=1132938
  31. Gupta K (2016) Oil price shocks, competition, and oil and gas stock returns—global evidence. Energy Econ 57:140–153Google Scholar
  32. Halıcı-Tülüce NS, Doğan İ, Dumrul C (2016) Is income relevant for health expenditure and economic growth nexus? Int J Health Econ Manag 16(1):23–49Google Scholar
  33. He LT (2006) Variations in effects of monetary policy on stock market returns in the past four decades. Rev Financ Econ 15(4):331–349Google Scholar
  34. Heidari H (2011) An alternative VAR model for forecasting iranian inflation: an application of Bewley transformation. Q Iran Econ Res 46:77–96Google Scholar
  35. Huang RD, Masulis RW, Stoll HR (1996) Energy shocks and financial markets. J Futures Mark 16(1):1–27Google Scholar
  36. Iqbal J (2017) Does gold hedge stock market, inflation and exchange rate risks? An econometric investigation. Int Rev Econ Financ 48:1–17Google Scholar
  37. Joarder MAM, Ahmed MU, Haque T, Hasanuzzaman S (2014) An empirical testing of informational efficiency in Bangladesh capital market. Econ Change Restruct 47(1):63–87Google Scholar
  38. Jones CM, Kaul G (1996) Oil and the stock markets. J Financ 51(2):463–491Google Scholar
  39. Kang W, Ratti RA, Yoon KH (2015) The impact of oil price shocks on the stock market return and volatility relationship. J Int Financ Mark Inst Money 34:41–54Google Scholar
  40. Kang W, Ratti RA, Vespignani J (2016) The impact of oil price shocks on the US stock market: a note on the roles of US and non-US oil production. Econ Lett 145:176–181Google Scholar
  41. Kang W, de Gracia FP, Ratti RA (2017) Oil price shocks, policy uncertainty, and stock returns of oil and gas corporations. J Int Money Financ 70:344–359Google Scholar
  42. Kim S, In F (2005) The relationship between stock returns and inflation: new evidence from wavelet analysis. J Empir Financ 12(3):435–444Google Scholar
  43. Konrad E (2009) The impact of monetary policy surprises on asset return volatility: the case of Germany. Fin Mark Portf Manag 23(2):111–135Google Scholar
  44. Li Q, Cheng K, Yang X (2017) Response pattern of stock returns to international oil price shocks: from the perspective of China’s oil industrial chain. Appl Energy 185:1821–1831Google Scholar
  45. Lichtenberg FR (2015) The impact of pharmaceutical innovation on premature mortality, cancer mortality, and hospitalization in Slovenia, 1997–2010. Appl Health Econ Health Policy 13(2):207–222Google Scholar
  46. Lichtenberg FR (2016) The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995–2012. Eur J Health Econ 17(7):833–854Google Scholar
  47. Malik F, Ewing BT (2009) Volatility transmission between oil prices and equity sector returns. Int Rev Financ Anal 18(3):95–100Google Scholar
  48. Mohammadzadeh M, Rahimi F, Rahimi F, Aarabi SM, Salamzadeh J (2013) The effect of capital structure on the profitability of pharmaceutical companies the case of Iran. Iran J Pharm Res IJPR 12(3):573Google Scholar
  49. Nelson DB (1991) Conditional heteroskedasticity in asset returns: a new approach. Econom J Econom Soc 59:347–370Google Scholar
  50. Nusair SA, Al-Khasawneh JA (2017) Oil price shocks and stock market returns of the GCC countries: empirical evidence from quantile regression analysis. Econ Change Restruct.  https://doi.org/10.1007/s10644-017-9207-4 Google Scholar
  51. Park K, Ratti RA (2000) Real activity, inflation, stock returns, and monetary policy. Financ Rev 35(2):59–78Google Scholar
  52. Rasekh HR, Mehralian G, Vatankhah-Mohammadabadi AA (2012) Situation analysis of R&D activities: an empirical study in Iranian pharmaceutical companies. Iran J Pharm Res IJPR 11(4):1013Google Scholar
  53. Rigobon R, Sack B (2004) The impact of monetary policy on asset prices. J Monet Econ 51(8):1553–1575Google Scholar
  54. Ruiz J (2015) Response of Spanish stock market to ECB monetary policy during financial crisis. Span Rev Financ Econ 13(2):41–47Google Scholar
  55. Rushdi M, Kim JH, Silvapulle P (2012) ARDL bounds tests and robust inference for the long run relationship between real stock returns and inflation in Australia. Econ Model 29(3):535–543Google Scholar
  56. Sadorsky P (1999) Oil price shocks and stock market activity. Energy Econ 21(5):449–469Google Scholar
  57. Scholtens B, Yurtsever C (2012) Oil price shocks and European industries. Energy Econ 34(4):1187–1195Google Scholar
  58. Sellin P (2001) Monetary policy and the stock market: theory and empirical evidence. J Econ Surv 15(4):491–541Google Scholar
  59. Sims CA (1980) Macroeconomics and reality. Econometrica 48(1):1–48Google Scholar
  60. Thorbecke W (1997) On stock market returns and monetary policy. J Financ 52(2):635–654Google Scholar
  61. Tiwari AK, Dar AB, Bhanja N, Arouri M, Teulon F (2015) Stock returns and inflation in Pakistan. Econ Model 47:23–31Google Scholar
  62. Vithessonthi C, Techarongrojwong Y (2012) The impact of monetary policy decisions on stock returns: evidence from Thailand. J Int Financ Mark Inst Money 22(3):487–507Google Scholar
  63. Wagner S, Wakeman S (2016) What do patent-based measures tell us about product commercialization? Evidence from the pharmaceutical industry. Res Policy 45(5):1091–1102Google Scholar
  64. Well DN (2007) Accounting for the effect of health on economic growth. Q J Econ 122(3):1265–1306Google Scholar
  65. Zartab S, Fatemi SF, Radmanesh R (2013) Fundamentals and stock return in pharmaceutical companies: a panel data model of Iranian industry. Iran J Pharm Sci 9(1):55–60Google Scholar
  66. Zhou Z, Yang S (2011) How do stock return movements behave in pharmaceutical industry? A 2008–2010 study. Master thesis. Umeå School of BusinessGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Hassan Heidari
    • 1
  • Arash Refah Kahriz
    • 1
  • Yousef Mohammadzadeh
    • 1
    Email author
  1. 1.Department of EconomicsUrmia UniversityUrmiaIran

Personalised recommendations